Skip to main content
SpringerLink
Log in

Glycopeptides and nephrotoxicity

  • Published:
Intensive Care Medicine Aims and scope Submit manuscript

Abstract

Infections due to Gram-positive bacteria have become an increasing problem in the ICU. Furthermore, multidrug resistance among Gram-positive pathogens is increasingly recognized. Empirical therapy with antibiotic regimens that are effective against Gram-positive pathogens is often required in the ICU. Many critically ill patients in the ICU have multiorgan system failure, including acute renal failure, which further impedes optimal antimicrobial therapy. In this communication, the use of glycopeptides in the ICU is briefly reviewed, and the occurrence of associated nephrotoxicity during therapy with vancomycin or teicoplanin, alone or in combination with an aminoglycoside, is examined. Finally, existing recommendations regarding the dose regimens of these agents in patients with renal impairment are evaluated, and guide-lines for optimizing glycopeptide therapy through improved pharmacokinetic monitoring are presented.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cheung RPF, Dipiro JT (1986) Vancomycin: an update. Pharmacotherapy 6:153–169

    Google Scholar 

  2. Sorrell TC, Packman DR (1982) Vancomycin therapy for methicillin resistant Staphylococcus aureus. Ann Intern Med 97:344–350

    Google Scholar 

  3. Farber BF, Moellering RC Jr (1983) Retrospective study of the toxicity of preparations of vancomycin from 1974–1981. Antimicrob Agents Chemother 23:138–141

    Google Scholar 

  4. Coppens L, Hauson B (1983) Therapy of staphylococcal infections with cefamandole or vancomycin alone or with a combination of cefamandole and tobramycin. Antimicrob Agents Chemother 23:36–41

    Google Scholar 

  5. Sorrell TC, Collignon PJ (1985) A prospective study of adverse reactions associated with vancomycin therapy. J Antimicrob Chemother 16:235–241.

    Google Scholar 

  6. Sheftel TG, Maden MT (1985) Methicillin resistant Staph. aureus osteomyelitis. Clin Orthop 198:231–239

    Google Scholar 

  7. Mellor JA, Kingdom J (1985) Vancomycin toxicity: a prospective study. J Antimicrob Chemother 15:773–780

    Google Scholar 

  8. Cimino MA, Rotstein C, Slaughter RL, Emrich LJ (1987) Relationship of serum antibiotic concentration to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy. Am J Med 83:1091–1097

    Google Scholar 

  9. Nahata MC (1987) Lack of nephrotoxicity in paediatric patients receiving concurrent vancomycin and aminoglycoside therapy. Chemotherapy 33:302–304

    Google Scholar 

  10. Eng RHK, Wynn L, Smith SM, Terson-Tumang F (1989) Effects of intravenous vancomycin on renal function. Chemotherapy 35:320–325

    Google Scholar 

  11. Downs NJ, Neihart RE, Dolezal JM, Hodges GR (1989) Mild nephrotoxicity associated with vancomycin use. Arch Intern Med 149:1777–1781

    Google Scholar 

  12. Goren MP, Baker DK Jr, Shenep JL (1989) Vancomycin does not enhance amikacin-induced tubular nephrotoxicity in children. Pediatr Infect Dis J 8:278–282

    Google Scholar 

  13. Gudmundsson GH, Jensen LJ (1989) Vancomycin and nephrotoxicity. Lancet I:625

    Google Scholar 

  14. Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH (1990) Nephrotoxicity of vancomycin alone and with an aminoglycoside. J Antimicrob Chemother 1990 25:679–687

    Google Scholar 

  15. Pauly DJ, Musa DM, Lestico MR, Lindstrom MJ, Hetsko CM (1990) Risk of nephrotoxicity with combination vancomycin aminoglycoside antibiotic therapy. Pharmacotherapy 10:378–382

    Google Scholar 

  16. Codding CE, Ramseyer L, Allan M, Pitha J, Rodriguez M (1989) Tubulointerstitial nephritis due to vancomycin. Am J Kidney Dis 14:512–515

    Google Scholar 

  17. Marre, R (1984) Renal tolerance and pharmacokinetics of vancomycin in rats. J Antimicrob Chemother 15:773–780

    Google Scholar 

  18. Ngeleka M, Beauchamp P, Tardif D, Auclair P, Gourde P, Bergeron MG (1990) Endotoxin increases the nephrotoxic potential of gentamicin and vancomycin plus gentamicin. J Infect Dis 161:721–727

    Google Scholar 

  19. Wold TJ, Turnipseed SA (1981) Toxicology of vancomycin in laboratory animals. Rev Infect Dis 3:S224–229

    Google Scholar 

  20. Wood CA, Kohlhepp SJ, Kohnen PW, Houghton DC, Gilbert DN (1986) Vancomycin enhancement of experimental tobramycin nephrotoxicity. Antimicrob Agents Chemother 30:20–24

    Google Scholar 

  21. Pryka RD, Rodvold KA, Erdman SM (1991) An updated comparison of drug dosing methods. Part IV: vancomycin. Clin Pharmacokinet 20:463–476

    Google Scholar 

  22. Antony KK, Lewis EW, Kenny MT, Dulworth JK, Brackman MB, Kuzma R, Yuh L, Eller MG, Thompson GA (1991) Pharmacokinetics and bioavailability of a new formulation of teicoplanin following intravenous and intramuscular administration to humans. J Pharm Sci 80:605–607

    Google Scholar 

  23. Matzke GR, McGory RW, Halstenson CE, Keane WF (1984) Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 25:433–437

    Google Scholar 

  24. Reed RL, Wu AH, Miller-Crotchett P, Crotchett J, Fischer RP (1989) Pharmacokinetic monitoring of nephrotoxic antibiotics in surgical intensive care patients. J Trauma 29:1462–1470

    Google Scholar 

  25. Rybak MJ, Albrecht LM, Berman JR, Warbasse LH, Svensson CK (1990) Vancomycin pharmacokinetics in burn patients and intravenous drug abusers. Antimicrob Agents Chemother 34:792–795

    Google Scholar 

  26. Moellering RC, Krogstad DJ, Greenblatt DJ (1981) Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med 94:343–346

    Google Scholar 

  27. Lake KD, Peterson CD (1985) A simplified dosing method for initiating vancomycin therapy. Pharmacotherapy 5:340–344

    Google Scholar 

  28. Rybak MJ, Boike SC (1986) Individualized adjustment of vancomycin dosage: comparison with two dosage nomograms. Drug Intell Clin Pharm 20:64–68

    Google Scholar 

  29. Hurst AK, Yoshinaga MA, Mitani GH, Foo KA, Jelliffe RW, Harrison EC (1990) Application of a Bayesian method to monitor and adjust vancomycin dosage regimens. Antimicrob Agents Chemother 34:1165–1171

    Google Scholar 

  30. Matzke GR, Kovarik JM, Rybak MJ, Boike SC (1985) Evaluation of the vancomycin-clearance:creatinine-clearance relationship for predicting vancomycin dosage. Clin Pharm 4:311–315

    Google Scholar 

  31. Zokufa HZ, Rodvold KA, Blum RA, Riff LJ, Fischer JH, Crossley KB, Rotschafer JC (1989) Simulation of vancomycin peak and trough concentrations using five dosing methods in 37 patients. Pharmacotherapy 9:10–16

    Google Scholar 

  32. Macias WL, Mueller BA, Scarim SK (1991) Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance. Clin Pharmacol Ther 50:688–694

    Google Scholar 

  33. De Bock V, Verbeelen D, Maes V, Sennesael J (1989) Pharmacokinetics of vancomycin in patients undergoing haemodialysis and haemofiltration. Nephrol Dial Transplant 4:635–639

    Google Scholar 

  34. Freeman CD, Quintiliani R, Nightingale CH (1993) Vancomycin therapeutic drug monitoring: is it necessary? DICP 27:594–597

    Google Scholar 

  35. Ackerman BH, Vannier AM (1992) Necessity of loading dose when using vancomycin in critically ill patients. J Antimicrob Chemother 28:460–461

    Google Scholar 

  36. Lewis P, Garaud JJ, Parenti F (1988) A multicentre open clinical trial of teicoplanin in infections caused by gram-positive bacteria. J Antimicrob Chemother 21 [Suppl A]:61–67

    Google Scholar 

  37. Frye RF, Jo ML, Dretler RH, Rosenbaum BJ (1992) Teicoplanin nephrotoxicity: first case report. Pharmacotherapy 12:240–242

    Google Scholar 

  38. Martino P, Micozzi A, Gentile G, Raccah R, Girmenia C, Mandelli F (1992) Piperacillin plus amikacin vs. piperacillin plus amikacin plus teicoplanin for empirical treatment of febrile episodes in neutropenic patients receiving quinolone prophylaxis. Clin Infect Dis 15:290–294

    Google Scholar 

  39. Charbouneau P, Garaud JJ, Aubertin J, Bazin C, Brunet S et al (1987) Efficacy and safety of teicoplanin plus netilmicin (T+N) compared to vancomycin plus netilmicin (V+N) in the treatment of severe Gram+ infections (abstract 82). Program and Abstracts of the 27th Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, New York, p 110

    Google Scholar 

  40. Smith SR, Cheesbrough J, Spearing R, Davies JM (1989) Randomized prospective study comparing vancomycin with teicoplanin in the treatment of infections associated with Hickman catheters. Antimicrob Agents Chemother 33:1193–1197

    Google Scholar 

  41. Davey PG, Williams AH (1991) A review of the safety profile of teicoplanin. J Antimicrob Chemother 27 [Suppl B]:69–73

    Google Scholar 

  42. Chow AW, Jewesson PJ, Kureishi A, Phillips GL (1993) Teicoplanin versus vancomycin in the empirical treatment of febrile neutropenic patients. Eur J Haematol 51 [Suppl 54]:18–24

    Google Scholar 

  43. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance form serum creatinine. Nephron 16:31–41

    Google Scholar 

  44. Rowland M (1990) Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet 18:184–209

    Google Scholar 

  45. Chambers HF, Kennedy S (1990) Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate of efficacy of teicoplanin in a rabbit model of endocarditis. Antimicrob Agents Chemother 34:510–514

    Google Scholar 

  46. Domart Y, Pierre C, Clair B, Garoud JJ, Regnier B, Gibert C (1987) Pharmacokinetics of teicoplanin in critically ill patients with various degrees of renal impairment. Antimicrob Agents Chemother 31:1600–1604

    Google Scholar 

  47. Falcoz C, Ferry N, Pozet N, Cuisinaud G, Zech PY, Sassard J (1987) Pharmacokinetics of teicoplanin in renal failure. Antimicrob Agents Chemother 31:1255–1262

    Google Scholar 

  48. Smithers JA, Thompson GA, Kenny MT, Dulworth JK, Kulmala HK, Lewis, EW, Ruberg, SJ, Shapiro Keane WF, Halstenson CE (1992) Applicability of teicoplanin dosage adjustment guidelines for renally impaired patients over the range of 3 to 30 mg/kg. Biopharm Drug Dispos 13:571–581

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Infectious Diseases, Department of Medicine, University of British Columbia and Vancouver General Hospital, 2733 Heather Street, V5Z 3J5, Vancouver, British Columbia, Canada

    A. W. Chow & R. M. Azar

Authors
  1. A. W. Chow
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. M. Azar
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chow, A.W., Azar, R.M. Glycopeptides and nephrotoxicity. Intensive Care Med 20 (Suppl 4), S23–S29 (1994). https://doi.org/10.1007/BF01713979

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01713979

Key words

Search

Navigation